

Supplementary appendix 2 Results for subgroup analyses

Subgroup	OS HR (95% CI)	PFS HR (95% CI)	ICER	Cost-effectiveness probability at the threshold of \$100000/QALY	Cost-effectiveness probability at the threshold of \$150000/QALY
Sex					
Male	0.70 (0.50–0.99)	0.66 (0.50–0.87)	172432	0	15%
Female	0.29 (0.19–0.44)	0.40 (0.29–0.54)	115344	3%	100%
Smoking status					
Current or former	0.54 (0.41–0.71)	0.54 (0.43–0.66)	151882	0	40%
Never	0.23 (0.10–0.54)	0.43 (0.23–0.81)	99695	36%	100%
PD-L1 tumor proportion score					
<1%	0.59 (0.38–0.92)	0.75 (0.53–1.05)	132478	1%	86%
1–49%	0.55 (0.34–0.90)	0.55 (0.37–0.81)	152694	0	38%
≥50%	0.42 (0.26–0.68)	0.36 (0.25–0.52)	154361	0	30%

PFS: progression-free survival; OS: overall survival; HR: hazard ratio; ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life year.